We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Assay Evaluated for Celiac Disease Screening

By LabMedica International staff writers
Posted on 07 Jun 2015
Celiac Disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten-containing grains in genetically susceptible individuals and it damages the small intestine mucosa leading to villous atrophy, crypt hyperplasia and intraepithelial lymphocytic infiltrate.

Small bowel biopsy is the conventional gold standard for the diagnosis of CD, but greater emphasis is now given to serological assays like anti-tissue Transglutaminase immunoglobulin (Ig) A antibodies (anti-tTGA), anti-Deamidated Gliadin Peptides IgA and IgG antibodies (a-DGP IgA/IgG) and anti-Endomysium IgA antibodies (EMA).

Scientists at the University of Naples Federico II (Italy) selected 730 children aged between six months and four years nominated Group A: 652 non-CD and 78 CD, and 348 children younger than two years nominated Group B: 327 non-CD and 21 CD which were part of Group A. More...
These groups were used to evaluate the agreement between anti-tTGA and a-DGP IgA/IgG by Kappa coefficient and to compare the diagnostic accuracy of anti-tTGA with that of a-DGP IgA/IgG by Receiver Operating Characteristic (ROC) curve analysis.

Sera from the groups were assayed for IgA and IgG antibodies a-DGP and IgA antibodies anti-tTG by enzyme-linked immunosorbent assay (ELISA) test (Delta Biologicals; Rome, Italy). The IgA antibodies anti-Endomysium were detected by Delta Biological’s Indirect Immunofluorescence (IFI) assay using sections of distal monkey esophagus mounted on glass slides at a starting dilution of 1:5, which was considered the threshold for positivity.

There was a substantial agreement between anti-tTGA and a-DGP IgA in Group A and an almost perfect agreement in Group B. The strength of agreement between anti-tTGA and a-DGP IgG was moderate in Group A and substantial in Group B. The anti-tTGA was more sensitive and specific than a-DGP IgA/IgG in both groups. The strongest point of the current study was the cutoff values being adjusted for the study population in case of all antibody assays according to Receiver Operator Characteristic (ROC) curve analysis.

The authors concluded that anti-tTGA, because of their high diagnostic accuracy, may be used as initial screening assay for CD in all subjects from six months of age, according to new European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Criteria 2012. The study was published on June 15, 2015, in the journal Clinica Chimica Acta.

Related Links:

University of Naples Federico II
Delta Biologicals 



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.